Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
NEO-COMBAT XL: Neoadjuvant and Maintenance XL092 and Cemiplimab in BRAF V600E-wildtype Anaplastic Thyroid Cancer: a Phase 1B Study
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants w…
Anaplastic Thyroid CancerThyroid CancerBRAF Mutation-Related Tumors
UNC Lineberger Comprehensive Cancer CenterNCT06902376
Phase 2
A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial
The goal of the trial is to improve this OS by 4 months (to 9.9 months) using the zanzalintinib + cemiplimab treatment combination. Given an accrual period of …
Anaplastic Thyroid Cancer
M.D. Anderson Cancer CenterNCT07470489